drugset / Trial / NCT03115112
Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to investigate the effect of bexagliflozin compared to sitagliptin as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).
Timeline
- Start
- 2017-10-12
- Primary completion
- 2018-10-31
- Completion
- 2018-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bexagliflozin | Small molecule | 20 mg | — |
| Comparator | Sitagliptin | Small molecule | 100 mg | — |